IRVINE, Calif., Oct. 1, 2012 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Charles Love to the position Vice President of Clinical Affairs. Mr. Love will be responsible for overseeing all Endologix U.S. and international clinical trials and will report to John McDermott, President and Chief Executive Officer. Janet Fauls, previously Vice President of Regulatory and Clinical Affairs, will maintain responsibility for overseeing Regulatory Affairs as the Company prepares for multiple upcoming potential regulatory milestones for its product pipeline.
Mr. McDermott, said, "Charles Love has more than twenty years of experience with medical devices in product development, regulatory strategy and clinical trial design. His extensive experience will be a valuable asset as we continue to advance our new product pipeline, including the U.S. clinical trials for the Ventana™ Fenestrated System and the Nellix® EndoVascular Aneurysm Sealing System. We look forward to Mr. Love joining our management team as we continue to expand our product portfolio and gain share in the AAA market."
Prior to joining Endologix, Mr. Love served as Vice President of Clinical and Regulatory Compliance at CircuLite, Inc., a privately held medical device company developing disruptive solutions for the treatment of chronic heart failure. He has also served as a consultant and held management level Clinical Affairs, Regulatory and Strategic Development positions for a variety of medical device companies, including Medtronic, CoreValve, nContact Surgical, Inc., Ventracor Limited, and Converge Medical, Inc. His experience also includes senior management positions at Ramus Medical Technologies and Autogenics. He serves on the Board of Directors for Loma Vista Medical and is on the Technical Advisory Board for Dexteritie Surgical.Mr. Love received a B.A. in Biology from Westmont College. He also completed undergraduate work in Engineering at Gonzaga University and completed management programs at the University of California and Stanford University.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts